氏名

所属

職名

取得学位

専門分野

主な論文・著作・業績①Katagiri, H., Yonezawa, H., Shitamura, S., Sugawara, A., Kawano, T., Maemondo, M., Nishiya, N. : A Wnt/βcatenin signaling inhibitor, IMU1003, suppresses the emergence of osimertinib-resistant colonies from gefitinibresistant non-small cell lung cancer cells./ Biochem Biophys Res Commun. 645:24-29 (2023)②Yonezawa, H., Ikeda, A., Takahashi, R., Endo, H., Sugawara, Y., Goto, M., Kanno, M., Ogawa, S., Nakamura, K.,Ujiie, H., Iwatsuki, M., Hirose, T., Sunazuka, T., Uehara, Y., Nishiya, N. : Ivermectin represses Wnt/β-cateninsignaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases./ iScience.

西谷直之

臨床薬学講座情報薬科学分野

創薬科学教授博士（薬学）

腫瘍治療学
ケミカルバイオロジー

25(3):103912 (2022)③Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu,K., Sakyo, T., Abe, M., Yonezawa, H., Ishibashi, F., Matsuura, M., Tomida, A., Seimiya, H., Yamori, T., Iwao, M.,Uehara, Y. : Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal GrowthFactor Receptor. / Cancer Sci., 112: 1963–1974 (2021)④文部科学省科学研究費補助金「課題名：ｍTORC構成因子Tel2を標的とする新規マクロライド系Wnt経路阻害薬の開発」2021〜2023年⑤特許

第7090252号「第四世代EGFRチロシンキナーゼ阻害剤」令和4年6月16日①Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu,K., Sakyo, T., Abe, M., Yonezawa, H., Ishibashi, F., Matsuura, M., Tomida, A., Seimiya, H., Yamori, T., Iwao, M.,
Uehara, Y. : Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal GrowthFactor Receptor. / Cancer Sci., 112: 1963–1974 (2021)②Yonezawa, H., Sugawara, A., Sakyo, T., Uehara, Y., Kawano, T., Nishiya, N. : IMU1003, an atrarate derivative,inhibits Wnt/β-catenin signaling. / Biochem. Biophys. Res. Commun. 532: 440-445 (2020)

佐京智子

臨床薬学講座情報薬科学分野

助教

博士（医学）

細胞生物学③ Watanabe, M., Naraba, H., Sakyo, T., Kitagawa, T. : DNA damage-induced modulation of GLUT3 expression is

病態医化学

mediated through p53-independent extracellular signal-regulated kinase signaling in HeLa cells. / Mol Cancer

腫瘍生物学

Res.8, 1547-57 (2010)④ Sakyo, T., Naraba, H., Teraoka, H., and Kitagawa, T. : The intrinsic structure of glucose transporter isoforms
Glut1 and Glut3 regulates their differential distribution to detergent-resistant membrane domains in non-polarized
mammalian cells. / FEBS Journal, vol. 274, 2843-2853 (2007)⑤ Sakyo, T., and Kitagawa, T. : Differential localization of glucose transporter isoformes in non-polarized
mammalian cells: Distribution of GLUT1 but not GLUT3 to detergent-resistant membrane domains. / Biochimica
Biophysica Acta(BBA)-Biomembranes, 1567: 165-175 (2002)

①氏家悠貴（著者）,中原保裕（監修）,今日の臨床サポート,がん免疫療法（薬理）,エルゼビア・ジャパン(2023)
https://clinicalsup.jp/jpoc/contentpage.aspx?diseaseid=2283.
②Yonezawa, H., Ikeda, A., Takahashi, R., Endo, H., Sugawara, Y., Goto, M., Kanno, M., Ogawa, S., Nakamura, K.,Ujiie, H., Iwatsuki, M., Hirose, T., Sunazuka, T., Uehara, Y., Nishiya, N. : Ivermectin represses Wnt/β-cateninsignaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases. / iScience.
7;25:103912(2022).

氏家悠貴

臨床薬学講座情報薬科学分野

助教

学士（薬学）

医療薬学
がん化学療法③Ujiie, H., Nihei, S., Nishiya, N., Goto, S., Asakura, Y., Miura, S., Hirai, D., Endo, M., Oyake, T., Ito, S., Chiba, T.,
Kudo, K. : Switching from Intravenous to Oral Tacrolimus Reduces its Blood Concentration in Paediatric Cancer
Patients. / Anticancer Res. 41:2591-2596 (2021)④Takahashi, H., Asaka, J., Tairabune, T., Ujiie, H., Matsuura, Y., Nihei, S., Kimura, T., Chiba, T., Kudo K. : Analysis ofrisk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination ofmethods for their avoidance. / J Clin Pharm Ther, Online ahead of print. doi: 10.1111/jcpt.13475. (2021)⑤Oku, Y., Tareyanagi, C., Takaya, S., Osaka, S., Ujiie, H., Yoshida, K., Nishiya, N., Uehara, Y. : Multimodal Effects ofSmall Molecule ROCK and LIMK Inhibitors on Mitosis, and Their Implication as Anti-Leukemia Agents. / PLoS
One, 9:e92402. (2014)